Zentalis Pharmaceuticals (ZNTL) Competitors $1.25 +0.01 (+0.81%) As of 07/3/2025 02:21 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZNTL vs. CKPT, VIGL, ETON, CMPX, ZYBT, TECX, SLDB, RZLT, HUMA, and ARCTShould you be buying Zentalis Pharmaceuticals stock or one of its competitors? The main competitors of Zentalis Pharmaceuticals include Checkpoint Therapeutics (CKPT), Vigil Neuroscience (VIGL), Eton Pharmaceuticals (ETON), Compass Therapeutics (CMPX), Zhengye Biotechnology (ZYBT), Tectonic Therapeutic (TECX), Solid Biosciences (SLDB), Rezolute (RZLT), Humacyte (HUMA), and Arcturus Therapeutics (ARCT). These companies are all part of the "pharmaceutical products" industry. Zentalis Pharmaceuticals vs. Its Competitors Checkpoint Therapeutics Vigil Neuroscience Eton Pharmaceuticals Compass Therapeutics Zhengye Biotechnology Tectonic Therapeutic Solid Biosciences Rezolute Humacyte Arcturus Therapeutics Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Checkpoint Therapeutics (NASDAQ:CKPT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings. Do institutionals & insiders hold more shares of ZNTL or CKPT? 22.0% of Checkpoint Therapeutics shares are owned by institutional investors. 1.9% of Zentalis Pharmaceuticals shares are owned by insiders. Comparatively, 2.1% of Checkpoint Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has more volatility and risk, ZNTL or CKPT? Zentalis Pharmaceuticals has a beta of 1.59, suggesting that its stock price is 59% more volatile than the S&P 500. Comparatively, Checkpoint Therapeutics has a beta of 1.18, suggesting that its stock price is 18% more volatile than the S&P 500. Does the media prefer ZNTL or CKPT? In the previous week, Zentalis Pharmaceuticals had 1 more articles in the media than Checkpoint Therapeutics. MarketBeat recorded 1 mentions for Zentalis Pharmaceuticals and 0 mentions for Checkpoint Therapeutics. Zentalis Pharmaceuticals' average media sentiment score of 0.00 beat Checkpoint Therapeutics' score of -0.69 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Zentalis Pharmaceuticals Neutral Checkpoint Therapeutics Negative Which has better valuation and earnings, ZNTL or CKPT? Checkpoint Therapeutics has lower revenue, but higher earnings than Zentalis Pharmaceuticals. Checkpoint Therapeutics is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZentalis Pharmaceuticals$67.43M1.33-$165.84M-$3.13-0.40Checkpoint Therapeutics$41K9,041.59-$51.85M-$1.29-3.30 Is ZNTL or CKPT more profitable? Checkpoint Therapeutics' return on equity of 0.00% beat Zentalis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Zentalis PharmaceuticalsN/A -65.48% -51.05% Checkpoint Therapeutics N/A N/A -659.07% Do analysts prefer ZNTL or CKPT? Zentalis Pharmaceuticals presently has a consensus price target of $8.37, suggesting a potential upside of 569.33%. Checkpoint Therapeutics has a consensus price target of $4.33, suggesting a potential upside of 1.72%. Given Zentalis Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Zentalis Pharmaceuticals is more favorable than Checkpoint Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zentalis Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50Checkpoint Therapeutics 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 SummaryZentalis Pharmaceuticals beats Checkpoint Therapeutics on 9 of the 15 factors compared between the two stocks. Get Zentalis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ZNTL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZNTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZNTL vs. The Competition Export to ExcelMetricZentalis PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$90.66M$2.89B$5.56B$9.04BDividend YieldN/A2.44%5.24%4.01%P/E Ratio-0.4021.7127.6620.25Price / Sales1.33281.81415.41118.18Price / CashN/A42.7336.8958.07Price / Book0.267.518.035.67Net Income-$165.84M-$55.14M$3.18B$249.21M7 Day Performance5.93%4.61%2.93%3.27%1 Month Performance-14.97%4.72%3.75%5.55%1 Year Performance-65.47%5.92%35.20%21.08% Zentalis Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZNTLZentalis Pharmaceuticals1.59 of 5 stars$1.25+0.8%$8.37+569.3%-64.1%$90.66M$67.43M-0.40160CKPTCheckpoint Therapeutics0.4851 of 5 stars$4.26flat$4.33+1.7%N/A$370.71M$41K-2.3210VIGLVigil Neuroscience3.3496 of 5 stars$7.94+0.3%$10.80+36.0%+102.3%$370.56MN/A-3.8740ETONEton Pharmaceuticals2.728 of 5 stars$13.51-0.4%$29.67+119.6%+341.5%$362.34M$39.01M-75.0620CMPXCompass Therapeutics3.3831 of 5 stars$2.54+5.8%$13.13+416.7%+238.4%$351.23M$850K-6.2020Analyst UpgradeZYBTZhengye BiotechnologyN/A$7.43-20.1%N/AN/A$350.47MN/A0.00278News CoverageLockup ExpirationTECXTectonic Therapeutic3.6145 of 5 stars$18.75-5.4%$82.33+339.1%+38.6%$350.06MN/A-2.56120Analyst UpgradeSLDBSolid Biosciences2.9312 of 5 stars$4.51-5.8%$14.90+230.4%-16.6%$349.57M$8.09M-1.51100Gap UpRZLTRezolute2.2667 of 5 stars$4.03-1.9%$11.83+193.6%+14.5%$344.64MN/A-3.5040HUMAHumacyte2.3483 of 5 stars$2.21-4.3%$11.71+430.1%-60.1%$342.82M$1.57M-3.20150ARCTArcturus Therapeutics3.7716 of 5 stars$12.51+1.8%$53.50+327.7%-37.8%$339.27M$152.31M-4.94180News CoverageAnalyst Forecast Related Companies and Tools Related Companies CKPT Competitors VIGL Competitors ETON Competitors CMPX Competitors ZYBT Competitors TECX Competitors SLDB Competitors RZLT Competitors HUMA Competitors ARCT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZNTL) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredThe #1 AI Energy StockNearly $600 billion is projected to be spent on AI data centers this year. That's because the ones being bu...Weiss Ratings | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zentalis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zentalis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
